ASSAN

Cynomolgus EGFR-CHO-K1 Stable Cell Line


Catalog Number Product Size Price
C3062 Cynomolgus EGFR-CHO-K1 Stable Cell Line 2 vials $6000 Order

Product Specifications


Catalog Number C3062
Cell Line Name Cynomolgus EGFR-CHO-K1 Stable Cell Line
Accession Number XP_005549616.1
Host Cell Adherent CHO-K1
Quantity Two vials of frozen cells (2x106 per vial)
Culture Medium DMEM with 10% FBS, 4 µg/ml puromycin
Freezing Medium 90% FBS and 10% DMSO
Storage Liquid nitrogen upon receipt
Product Datasheet: Download PDF

Representative Data


Detection of cyno EGFR expression on cyno EGFR-CHO-K1 stable cells using a monoclonal antibody specific for human EGFR (R&D, #FAB9577P)


Background


Epidermal growth factor receptor (EGFR), also known as ErbB-1, is a transmembrane receptor protein that belongs to the receptor tyrosine kinase family. It is encoded by the EGFR gene and is expressed in various tissues, including the epithelial cells of the skin, lung, gastrointestinal tract, and brain. EGFR is involved in several cellular processes, including cell growth, proliferation, differentiation, and survival, through activation of downstream signaling pathways such as the MAPK/ERK and PI3K/Akt pathways. However, dysregulation of EGFR signaling has been linked to cancer development and progression in various cancers, including non-small cell lung, head and neck, colorectal, and pancreatic cancers. Therefore, EGFR has become an attractive therapeutic target in oncology. Small molecular inhibitors, such as gefitinib, erlotinib, and afatinib, and monoclonal antibodies, such as cetuximab and panitumumab, have been developed to target EGFR for the treatment of various cancers, particularly in patients with EGFR mutations or overexpression.

References

Carpenter G. Annual Review of Biochemistry. 56: 881–914, 1987.

Pai, R., Soreghan, B., Szabo, I. L., Pavelka, M., Baatar, D., Tarnawski, A. S. Nature Med. 8: 289-293, 2002.

Reynolds, F. H., Jr., Todaro, G. J., Fryling, C., Stephenson, J. R. Nature. 292: 259-262, 1981.

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., Mardis, E., Kupfer, D., Wilson, R., Kris, M., Varmus, H. Proc. Nat. Acad. Sci. 101: 13306-13311, 2004.

Nakamura JL. Expert Opinion on Therapeutic Targets. 11 (4): 463–72, 2007.